Quality of bone: What effects of treatment can be monitored and what does it require?;Kvalita kosti: Které účinky léčby måžeme monitorovat a co to předpokládá?

Osteologicky Bulletin

Volumn 8, Issue 3, 2003, Pages 75-81

  Štepán, Jan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Bisphosphonates; Bone markers; Bone mineral; Monitoring; Quality of bone

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTRADIOL; RALOXIFENE;

ARTICLE; BONE; BONE DENSITY; BONE MINERAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; QUANTITATIVE ANALYSIS; STANDARDIZATION; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0142240090     PISSN: 12113778     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998;13:1747-54.
2. Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002;162:1140-3.
3. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos lnt 1999;9:461-8.
4. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.
5. Cranney A, Tugwell P, Adachi J, et al. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:517-523.
6. Cranney A. Wells G. Willan A, et al. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23:508-516.
7. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:524-528.
8. Wells G, Tugwell P, Shea B, et al. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:529-539.
9. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:540-551.
10. van Beek E, Pieterman E, Cohen L, et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999;264:108-11.
11. Reszka AA, Halasy Nagy JM, Masarachia PJ, et al. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mstl kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 1999;274:34967-73.
12. Bergstrom JD, Bostedor RG, Masarachia PJ, et al. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000;373:231-41.
13. Benford HL, Frith JC, Auriola S, et al. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999;56:131-40.
14. Colucci S, Minielli V, Zambonin G, et al. Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int 1998;63:230-5.
15. Benford HL, McGowan NW, Helfrich MH, et al. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001;28:465-73.
16. Still K, Phipps RJ, Scutt A. Effects of risedronate, alendronate, and etidronate on the viability and activity of rat bone marrow stromal cells in vitro. Calcif Tissue Int 2003;72:145-150.
17. Eriksen EF, Melsen F, Sod E, et al. Effect of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 2002;31:620-625.
18. Currey JD. Changes in the impact energy absorption of bone with age. J Biomech 1979;12:459-69.
19. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000;21:115-37.
20. Boivin GY, Chavassieux PM, Santora AC, et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000;27:687-94.
21. Meunier PJ, Boivin G. Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone 1997;21:373-7.
22. Boivin G, Meunier PJ. Effects of bisphosphonates on matrix mineralization. J Musculoskel Neuron Interact 2002:2:538-543.
23. Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001;28:524-31.
24. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535-41.
25. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995:333:1437-43.
26. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
27. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000;85:3109-15.
28. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
29. Khastgir G, Studd J, Holland N, et al. Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study. J Clin Endocrinol Metab 2001;86:289-95.
30. Writing Group for the Women's Health Initiative 1. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
31. Taranta A, Braina M, Teti A, et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 2002;30:368-76.
32. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17.
33. Meunier PJ, Sebert JL, Reginster JY, et al. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy. Osteoporos Int 1998;8:4-12.
34. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-34.
35. Silverman SL, Greenwald M, Klein RA, et al. Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Obstet Gynecol 1997;89:321-5.
36. Blake GM, Fogelman I. The role of bone density measurements in the evaluation of new treatments for osteoporosis. Curr Pharm Des 2002;8:1885-1905.
37. Compston JE. Do we need to monitor anti-osteoporosis is treatment anyway? Calcif Tissue Int 2003;72:328.
38. Cummings SR, Palermo L, Browner W, et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 2000;283:1318-21.
39. Štěpán JJ, Zikan V. Calcitonin load test to assess the efficacy of salmon calcitonin. Clin Chim Acta 2003;v tisku.
40. Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 1999;42:1246-54.
41. Courtney AC, Wachtel EF, Myers ER, et al. Effects of loading rate on strength of the proximal femur [published erratum appears in Calcif Tissue Int 1994 Nov;55:402]. Calcif Tissue Int 1994;55:53-8.
42. Courtney AC, Wachtel EF, Myers ER, et al. Effects of loading rate on strength of the proximal femur [published erratum appears in Calcif Tissue Int 1994 Nov;55:402]. Calcif Tissue Int 1994;55:53-8.
43. Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001;12:989-95.
44. Kanis JA, Johnell O, Oden A, et al. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 2000;27:585-90.
45. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Geneva: World Health Organisation: 1994.
46. Kanis JA. Assessing the risk of vertebral osteoporosis. Singapore Med J 2002;43:100-5.
47. Miller PD, Zapalowski C, Kulak CA, et al. Bone densitometry: the best way to detect osteoporosis and to monitor therapy. J Clin Endocrinol Metab 1999;84:1867-71.
48. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002;288:1889-97.
49. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 2000;11:192-202.
50. Bonnick SL, Johnston CC, Jr., Kleerekoper M, et al. Importance of precision in bone density measurements. J Clin Densitom 2001;4:105-10.
51. Cummings SR, Parfitt AM. Bone density regression to the mean and the individual patient. J Clin Endocrinol Metab 2001;86:4001-2.
52. Haddaway MJ, Darle Davie MW, McCall IW. Bone mineral density in healthy normal women and reproducibility of measurements in spine and hip using dual-energy X-ray absorptiometry. Br J Radiol 1992;65(771):213-7.
53. Sievanen H, Koskue V, Rauhio A, et al. Peripheral quantitative computed tomography in human long bones: evaluation of in vitro and in vivo precision. J Bone Miner Res 1998;13:871-82.
54. Heilmann P, Wuster C, Prolingheuer C, et al. Measurement of forearm bone mineral density: comparison of precision of five different instruments. Calcif Tissue Int 1998;62:383-7.
55. Michaeli DA, Mirshahi A, Singer J, et al. A new x-ray based osteoporosis screening tool provides accurate and precise assessment of phalanx bone mineral content. J Clin Densitom 1999;2:23-30.
56. Sievanen H, Oja P, Vuori I. Precision of dual-energy x-ray absorptiometry in determining bone mineral density and content of various skeletal sites. J Nucl Med 1992;33:1137-42.
57. Gluer CC. Quantitative ultrasound techniques for the assessment of osteoporosis: expert agreement on current status. The International Quantitative Ultrasound Consensus Group. J Bone Miner Res 1997;12:1280-8.
58. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52.
59. Boivin G, Chavassieux P, Meunier P. Histomorphometry of bone. Effects of different treatments on bone remodeling and mineralization. Osteologicky Bull 2002;7:5-9.
60. Roschger P, Rinnerthaler S, Yates J, et al. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001;29:185-91.
61. Weichetova M, Štěpán JJ, Michalska D, et al. COLIA1 polymorphism contributes to bone mineral density to assess prevalent wrist fractures. Bone 2000;26:287-90.
62. Garnero P, Cloos P, Sornay Rendu E, et al. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: The OFELY prospective study. J Bone Miner Res 2002;17:826-833.
63. Genant HK, Gordon C, Jiang Y, et al. Advanced imaging of the macrostructure and microstructure of bone. Horm Res 2000;54(Suppl 1):24-30.
64. Majumdar S. Magnetic resonance imaging of trabecular bone structure. Top Magn Reson Imaging 2002;13:323-34.
65. Faulkner KG, Cummings SR, Nevitt MC, et al. Hip axis length and osteoporotic fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1995;10:506-8.
66. Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000;15:1526-36.
67. van den Bergh JP, van Lenthe GH, Hermus AR, et al. Speed of sound reflects Young's modulus as assessed by microstructural finite element analysis. Bone 2000;26:519-24.
68. Njeh CF, Hans D, Li J, et al. Comparison of six caleaneal quantitative ultrasound devices: precision and hip fracture discrimination. Osteoporos Int 2000;11:1051-62.
69. Garnero P. Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 2000;11(Suppl 6):55-65.
70. Eastell R, Garnero P, Vrijens B, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: The IMPACT Study. Calcif Tissue Int 2003;72:408.
71. Bjarnason NH, Sarkar S, Duong T, et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001;12:922-30.
72. Hannon R, Blumsohn A, Naylor K, et al. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998;13:1124-33.
73. Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000;11:612-17.
74. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76.
75. Seibel MJ, Lang M, Geilenkeuser WJ. Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 2001;47:1443-50.